Last year’s top-selling drug was AbbVie’s injectable medication Humira®, bringing in nearly $20 billion in the U.S.
Coming in second was Merck’s cancer-fighting blockbuster Keytruda® at $14.4 billion, followed by Pfizer’s and Bristol Myers Squibb’s blood-thinning medication Eliquis® at $14.1 billion.
Just these three medications brought in nearly $50 billion for four pharmaceutical companies.
Below is a list of the Top 50 money-makers that earned pharmaceutical companies their highest revenues in 2020:
- Humira — $19.8 billion
- Keytruda — $14.4 billion
- Eliquis — $14.1 billion
- Revlimid — $12.1 billion
- Eylea — $10.7 billion
- Imbruvica — $9.4 billion
- Dupixent — $8.1 billion
- Stelara — $7.7 billion
- Biktarvy — $7.3 billion
- Opdivo — $7 billion
- Xarelto — $6.5 billion
- Prevnar 13 — $5.8 billion
- Ibrance — $5.4 billion
- Avastin — $5.3 billion
- Januvia / Janumet — $5.3 billion
- Trulicity — $5.1 billion
- Enbrel — $5 billion
- Ocrevus — $4.6 billion
- Rituxan — $4.5 billion
- Xtandi — $4.4 billion
- Tagrisso — $4.3 billion
- Darzalex — $4.2 billion
- Perjeta — $4.1 billion
- Cosentyx — $4 billion
- Herceptin — $3.9 billion
- Gardasil / Gardasil 9 Vaccine — $3.9 billion
- Avonex / Plegridy — $3.9 billion
- Tecfidera — $3.8 billion
- Remicade — $3.7 billion
- Invega sustenna — $3.6 billion
- Genvoya — $3.3 billion
- Ozempic — $3.2 billion
- Orencia — $3.1 billion
- Lantus — $3.1 billion
- Acremra / RoActemra — $3.1 billion
- Pomalyst / Imnovid — $3.1 billion
- Gilenya — $3 billion
- Triumeq — $2.9 billion
- Tecentriq — $2.9 billion
- Victoza — $2.9 billion
- Veklury — $2.8 billion
- Prolia — $2.8 billion
- Symbicort — $2.7 billion
- Humalog — $2.6 billion
- NovoRapid / NovoLog — $2.6 billion
- Entresto — $2.5 billion
- Zytiga — $2.5 billion
- Xeljanz — $2.4 billion
- Hemlibra — $2.3 billion